EVFM insider filings

Evofem Biosciences, Inc. — 47 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-01-12. Screen EVFM transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for EVFM between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Evofem Biosciences, Inc.

FiledFormInsiderReported transactionsSource
2024-01-124Zhang Yan — CFOSale (S): 104 @ $0.04EDGAR
2023-12-224Kamdar Kim P. — DirectorSale (S): 10 @ $0.62EDGAR
2023-04-264PELLETIER SAUNDRA L — Chief Executive Officer, DirectorDisposition to issuer (D): 50,000 @ $0EDGAR
2022-05-314PELLETIER SAUNDRA L — Chief Executive Officer, DirectorPurchase (P): 141,000 @ $0.35EDGAR
2022-05-064O'Brien Anthony Stephen — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2022-05-064Rutherford Colin — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2022-05-064Rarick Lisa Dale — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2022-05-064Greer Gillian — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2022-05-064Kamdar Kim P. — DirectorGrant/award (A): 6,000 (derivative) @ $0EDGAR
2022-02-234File Justin J. — Chief Financial OfficerGrant/award (A): 450,000 @ $0 · Grant/award (A): 450,000 (derivative) @ $0EDGAR
2022-02-234Fitzpatrick Alexander A — General Counsel and SecretaryGrant/award (A): 300,000 @ $0 · Grant/award (A): 300,000 (derivative) @ $0EDGAR
2022-02-234PELLETIER SAUNDRA L — Chief Executive Officer, DirectorGrant/award (A): 750,000 @ $0 · Grant/award (A): 750,000 (derivative) @ $0EDGAR
2022-01-044File Justin J. — Chief Financial OfficerDisposition to issuer (D): 120,000 @ $0EDGAR
2022-01-044Fitzpatrick Alexander A — General Counsel and SecretaryDisposition to issuer (D): 120,000 @ $0EDGAR
2022-01-044PELLETIER SAUNDRA L — Chief Executive Officer, DirectorDisposition to issuer (D): 300,000 @ $0EDGAR
2021-12-204File Justin J. — Chief Financial OfficerPurchase (P): 40,594 @ $0.37EDGAR
2021-12-204Fitzpatrick Alexander A — General Counsel and SecretaryPurchase (P): 25,000 @ $0.39EDGAR
2021-12-204PELLETIER SAUNDRA L — Chief Executive Officer, DirectorPurchase (P): 135,000 @ $0.38EDGAR
2021-07-094Barrans Russell — Chief Commercial OfficerTax withholding (F): 19,998 @ $0.97EDGAR
2021-06-214Kamdar Kim P. — DirectorPurchase (P): 10,000 @ $1.17EDGAR
2021-06-144Rarick Lisa Dale — DirectorPurchase (P): 5,000 @ $1.20EDGAR
2021-06-144O'Brien Anthony Stephen — DirectorPurchase (P): 8,140 @ $1.31EDGAR
2021-06-114Barrans Russell — Chief Commercial OfficerPurchase (P): 18,180 @ $1.14EDGAR
2021-06-104File Justin J. — Chief Financial OfficerPurchase (P): 24,500 @ $1.03EDGAR
2021-06-104Fitzpatrick Alexander A — General Counsel and SecretaryPurchase (P): 10,000 @ $1.02EDGAR
2021-06-104PELLETIER SAUNDRA L — Chief Executive Officer, DirectorPurchase (P): 50,000 @ $1.03EDGAR
2021-05-214Barrans Russell — Chief Commercial OfficerTax withholding (F): 31,480 @ $0.86EDGAR
2021-05-214Culwell Kelly — Chief Medical OfficerTax withholding (F): 42,061 @ $0.86EDGAR
2021-05-214File Justin J. — Chief Financial OfficerTax withholding (F): 42,280 @ $0.86EDGAR
2021-05-214Fitzpatrick Alexander A — General Counsel and SecretaryTax withholding (F): 42,120 @ $0.86EDGAR
2021-05-214PELLETIER SAUNDRA L — Chief Executive Officer, DirectorTax withholding (F): 105,300 @ $0.86EDGAR
2021-05-134Greer Gillian — DirectorGrant/award (A): 90,000 (derivative) @ $0EDGAR
2021-05-134Rutherford Colin — DirectorGrant/award (A): 90,000 (derivative) @ $0EDGAR
2021-05-134Rarick Lisa Dale — DirectorGrant/award (A): 90,000 (derivative) @ $0EDGAR
2021-05-134O'Brien Anthony Stephen — DirectorGrant/award (A): 90,000 (derivative) @ $0EDGAR
2021-05-134Hall William Walmsley — DirectorGrant/award (A): 90,000 (derivative) @ $0EDGAR
2021-05-134Kamdar Kim P. — DirectorGrant/award (A): 90,000 (derivative) @ $0EDGAR
2021-03-094PELLETIER SAUNDRA L — Chief Executive Officer, DirectorPurchase (P): 45,249 @ $2.28EDGAR
2021-02-034Barrans Russell — Chief Commercial OfficerGrant/award (A): 200,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0EDGAR
2021-02-034File Justin J. — Chief Financial OfficerGrant/award (A): 200,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0EDGAR
2021-02-034Culwell Kelly — Chief Medical OfficerGrant/award (A): 200,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0EDGAR
2021-02-034Fitzpatrick Alexander A — General Counsel and SecretaryGrant/award (A): 200,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0EDGAR
2021-02-034PELLETIER SAUNDRA L — Chief Executive Officer, DirectorGrant/award (A): 500,000 @ $0 · Grant/award (A): 700,000 (derivative) @ $0EDGAR
2020-11-184File Justin J. — Chief Financial OfficerPurchase (P): 7,760 @ $2.17EDGAR
2020-11-184Fitzpatrick Alexander A — General Counsel and SecretaryPurchase (P): 9,090 @ $2.20EDGAR
2020-09-114Barrans Russell — Chief Commercial OfficerPurchase (P): 1,000 @ $2.71 · Purchase (P): 3,000 @ $2.08EDGAR
2020-09-104PELLETIER SAUNDRA L — Chief Executive Officer, DirectorSale (S): 122,500 @ $3.26EDGAR

Recent 8-K events — Evofem Biosciences, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-188-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-158-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-238-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-208-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-148-K1.01 — Entry into a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-188-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-308-K1.01 — Entry into a Material Definitive Agreement
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-168-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-03-198-K1.02 — Termination of a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=EVFM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs